Human T cells were purified from peripheral blood mononuclear cells of healthy donors with an EasySep™ Human T-cell Enrichment kit (STEMCELL Technologies Inc., Vancouver, BC). They were then activated by human T-Activator DanyBeads (Life Technologies, Grand Island, NY) and expanded in complete RPMI-1640 medium in 96-well plates (105 cells/ml) in the presence of recombinant human IL-2 (20 ng/ml) (PeproTech, Rocky Hill, NJ) for 4 days. After washing with RPMI-1640 medium, T cells were co-cultured at a 3:1 or 2:1 ratio with PLX4032- or DMSO-pretreated cancer cells (2×104 cells/well) in a 96-well plate for 24 h. Alternatively, activated T cells were pre-incubated with an anti-human TRAIL neutralizing antibody for 1 h at 4°C before being utilized for co-culture with the tested cancer cells. After gentle removal of T cells from the culture system, cancer cells were subjected to 3-(4,5- dimethylhiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described. 25 (link) Cell survival was calculated by comparison to control cancer cells not exposed to T cells.
Human t activator danybeads
Manufactured by Thermo Fisher Scientific
The Human T-Activator DanyBeads is a laboratory product designed to activate human T cells. It consists of paramagnetic beads coated with antibodies that bind to and stimulate T cell receptors, promoting T cell proliferation and activation. The core function of this product is to enable the activation and expansion of human T cells for various research and experimental applications.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using human t activator danybeads
1
T-cell-mediated cancer cell killing
2
T-cell-mediated cancer cell killing
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Human T cells were purified from peripheral blood mononuclear cells of healthy donors with an EasySep™ Human T-cell Enrichment kit (STEMCELL Technologies Inc., Vancouver, BC). They were then activated by human T-Activator DanyBeads (Life Technologies, Grand Island, NY) and expanded in complete RPMI-1640 medium in 96-well plates (105 cells/ml) in the presence of recombinant human IL-2 (20 ng/ml) (PeproTech, Rocky Hill, NJ) for 4 days. After washing with RPMI-1640 medium, T cells were co-cultured at a 3:1 or 2:1 ratio with PLX4032- or DMSO-pretreated cancer cells (2×104 cells/well) in a 96-well plate for 24 h. Alternatively, activated T cells were pre-incubated with an anti-human TRAIL neutralizing antibody for 1 h at 4°C before being utilized for co-culture with the tested cancer cells. After gentle removal of T cells from the culture system, cancer cells were subjected to 3-(4,5- dimethylhiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described. 25 (link) Cell survival was calculated by comparison to control cancer cells not exposed to T cells.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!